The present invention relates to linear guanidine derivatives, methods of preparation, uses and pharmaceutical compositions thereof. The compounds of Formulas 1 or 2 exhibit high antimicrobial activity against Gram positive and Gram negative bacteria.

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

The invention relates to a surfactant composition comprising an ionic liquid prepared from an unsubsituted or substituted primary, secondary or tertiary amine, or from an unsubstituted or substituted pyridine, amidine or guanidine with at least one fatty acid and/or resin acid. The invention also relates to a method for treating bitumen froth from a separation process, where bitumen is separated from mineral solids. The method comprises addition of said surfactant composition to the diluent and/or to the froth before phase separation.

The use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odourless and nonvolatile at room temperature and accelerates the crosslinking of curable compositions very efficiently, without impairing the storage stability thereof. It is particularly suitable for compositions based on polymers containing silane groups, where it has very good compatibility, as a result of which such compositions do not have a tendency to separation or migration or evaporation of the catalyst.

The use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odourless and nonvolatile at room temperature and accelerates the crosslinking of curable compositions very efficiently, without impairing the storage stability thereof. It is particularly suitable for compositions based on polymers containing silane groups, where it has very good compatibility, as a result of which such compositions do not have a tendency to separation or migration or evaporation of the catalyst.

In one aspect, the present disclosure relates to click-functional antimicrobial molecules (including small molecules or, in some cases, macromolecules) and the construction of antimicrobial polymers such as polyurethanes, polyesters, and polyacrylates, including through the use of such molecules. In some cases, the antimicrobial click-functional molecules are based on 1,2-benzisothiazolin-3-one (BIT), trimethylguanidine or tetramethylguanidine (TMG), polyhexamethylene guanidine (PHMG), fluorine-containing molecules, or a combination thereof. For example, 1,2-benzisothiazolin-3-one (BIT) functionalized with an alkyne (BIT-Al), trimethylguanidine or tetramethylguanidine (TMG) functioned with an alkyne (TMG-Al) or dual alkynes (TMG-dAl), and/or polyhexamethylene guanidine (PHMG) functionalized with an alkyne (PHMG-Al) are described herein. Clickable antimicrobial polymers can be used to form coatings or films.

Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease.

Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease.

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.